Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department

Overview

The main objective of this cohort is to characterize COVID-19 patients hospitalized in infectious disease department. The collection of clinical and biological data from start of hospitalization to long-term follow up will contribute to a better description of the patient care, to the identification of predisposition to complication related to the disease, and to the evaluation of the impact of different therapeutical strategies.

Full Title of Study: “Caracterisation of SARS-Cov2 Infected Patients Hospitalized in Infectious Disease Department”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Retrospective
• Study Primary Completion Date: December 31, 2021

Interventions

• Other: Hospitalisation for SARS-COV2 infection
  • Patients hospitalized for SARS-COV2 infection

Clinical Trial Outcome Measures

Primary Measures

• Clinical characteristics
  • Time Frame: 34 months
  • Describe the clinical characteristic of patients hospitalized for SARS-CoV- 2 infection Identify factors associated with the COVID-19 disease severity
• Biological characteristics
  • Time Frame: 34 months
  • Describe the biological characteristic of patients hospitalized for SARS-CoV- 2 infection Identify factors associated with the COVID-19 disease severity
• Radiological characteristics
  • Time Frame: 34 months
  • Describe the radiological characteristic of patients hospitalized for SARS-CoV- 2 infection Identify factors associated with the COVID-19 disease severity

Secondary Measures

• Number of patient hospitalised for Covid-19
  • Time Frame: 34 months
  • Inpatient up to Day 28 or discharge
• Overall Inpatient Mortality
  • Time Frame: 34 months
  • Number of death due to Covid-19
• Requirement for mechanical ventilation
  • Time Frame: 34 months
  • Number of patients requiring mechanical ventilation
• ICU Length of Stay (LOS)
  • Time Frame: 34 months
  • Duration measured in days
• Evolution of patient general state during hospitalisation
  • Time Frame: 34 months
  • the different measures (Body Mass Index (BMI), respiratory rate at rest, peripheral oxygen saturation, need for oxygen supplementation, body temperature) will be aggregated in order to obtain a clinical status corresponding to the clinical evolution (good or bad) of the patient’s general state.
• Biological tests
  • Time Frame: 34 months
  • Dosage of Lymphocytes, C-reactive protein and IL-6

Participating in This Clinical Trial

Inclusion Criteria

• Age > or = to 18 – Patients hospitalised for SARS-CoV-2 infection confirmed by RT PCRand/or CT scan and/or serology Exclusion Criteria:

• Patients for whom SARS-CoV-2 infection has not been confirmed

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Centre Hospitalier Universitaire de Nice
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Contact(s)
  • Michel CARLES, +33492035847, carles.m@chu-nice.fr